#Cardiovascular outcomes
MACE, HFpEF, CV death, the trials that move guidelines.
Semaglutide vs SGLT2is in Kidney Disease
A new network meta-analysis compares semaglutide, SGLT2 inhibitors and finerenone on heart and kidney outcomes in diabetic kidney disease.
Oral Semaglutide and Cardiovascular Risk
A new observational study links oral semaglutide to fewer heart attacks and strokes than other diabetes drugs.
Semaglutide and Heart Risk in HIV
A new randomized trial found semaglutide improved calculated heart-disease risk and inflammation markers in adults with HIV, but not artery stiffness.
GLP-1 use before bariatric surgery
A matched retrospective study linked prior GLP-1RA or tirzepatide use to lower recorded early cardiorenal events after bariatric surgery.
Semaglutide ASCVD cost model
A US veteran model found lifetime semaglutide added 1.31 QALYs but cost $118,996 per QALY at an assumed $14,000 annual price.
How Incretin Drugs Affect the Heart
A new review finds heart benefits from incretin drugs like tirzepatide and retatrutide involve pathways beyond blood sugar control.
Combining Tesamorelin, Ipamorelin and TRT
A reddit user's heart rate spiked to 151 bpm after combining tesamorelin, ipamorelin and TRT. Here is what the evidence on each actually shows.
Retatrutide and Heart-Risk Biomarkers
A post hoc analysis of two retatrutide Phase 2 trials found large drops in atherogenic lipoproteins and CRP, not proof of fewer cardiovascular events.
Tirzepatide, blood pressure, cholesterol
A SURMOUNT post hoc analysis scores tirzepatide on all three targets at once. Between 32% and 38% of participants hit every one. Composites read differently.
Beyond weight loss: GLP-1 organ outcomes
A JACC editorial reframes GLP-1 drugs as cardiometabolic medicines. The SELECT, FLOW and SOUL trials, and the approved labels, already point that way.
Surgery vs semaglutide for heart outcomes
A large real-world study compared semaglutide with bariatric surgery on heart outcomes in obesity. Here is what it found and what it cannot prove.
Tirzepatide and heart events: BMJ study
A 2026 BMJ cohort linked tirzepatide to fewer cardiovascular events than sitagliptin, but the result remains observational.